Found: 16
Select item for more details and to access through your institution.
Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 12, p. 1456, doi. 10.1177/0091270009344335
- By:
- Publication type:
- Article
Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects.
- Published in:
- Diabetes Care, 2014, v. 37, n. 9, p. 2609, doi. 10.2337/dc14-0210
- By:
- Publication type:
- Article
Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.
- Published in:
- Toxicologic Pathology, 2017, v. 45, n. 3, p. 402, doi. 10.1177/0192623317696283
- By:
- Publication type:
- Article
Nizatidine, an H<sub>2</sub>-Receptor Antagonist: Disposition and Safety in the Elderly.
- Published in:
- 1987
- By:
- Publication type:
- Other
Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits.
- Published in:
- Clinical Endocrinology, 2000, v. 52, n. 2, p. 225, doi. 10.1046/j.1365-2265.2000.00919.x
- By:
- Publication type:
- Article
Secretion of nizatidine into human breast milk after single and multiple doses.
- Published in:
- Clinical Pharmacology & Therapeutics, 1990, v. 47, n. 6, p. 724, doi. 10.1038/clpt.1990.100
- By:
- Publication type:
- Article
Absorption studies of the H<sub>2</sub>-blocker nizatidine.
- Published in:
- Clinical Pharmacology & Therapeutics, 1987, v. 42, n. 5, p. 514, doi. 10.1038/clpt.1987.190
- By:
- Publication type:
- Article
Duloxetine: clinical pharmacokinetics and drug interactions.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 5, p. 311, doi. 10.2165/11319330-000000000-00000
- By:
- Publication type:
- Article
Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Population Pharmacokinetics of Orally Administered Duloxetine in Patients.
- Published in:
- Clinical Pharmacokinetics, 2009, v. 48, n. 3, p. 189, doi. 10.2165/00003088-200948030-00005
- By:
- Publication type:
- Article
In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine.
- Published in:
- Clinical Pharmacokinetics, 2008, v. 47, n. 3, p. 191, doi. 10.2165/00003088-200847030-00005
- By:
- Publication type:
- Article
Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women.
- Published in:
- Clinical Pharmacokinetics, 2008, v. 47, n. 2, p. 103, doi. 10.2165/00003088-200847020-00003
- By:
- Publication type:
- Article
Pharmacokinetics and Tolerability of Duloxetine following Oral Administration to Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacokinetics, 2007, v. 46, n. 9, p. 767, doi. 10.2165/00003088-200746090-00004
- By:
- Publication type:
- Article
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 73, n. 3, p. 170, doi. 10.1067/mcp.2003.28
- By:
- Publication type:
- Article